Aastrom Reports Data and Safety Monitoring Board Recommendation to Continue ixCELL-DCM Clinical Trial
09. April 2014 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Announces Appointments of Dr. Ross Tubo as Chief Scientific Officer and Dr. David Recker as Chief Medical Officer
01. April 2014 08:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 1, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present at the 2014 Regen Med Investor Day
19. März 2014 09:02 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 19, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Fourth-Quarter and Year-End 2013 Financial Results
13. März 2014 16:05 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 13, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Host Fourth Quarter 2013 Investor Call on March 13, 2014
06. März 2014 16:05 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 6, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences Enters Into $15 Million Equity Commitment With Lincoln Park Capital
27. Januar 2014 16:05 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
19. Dezember 2013 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences Regains Compliance With NASDAQ Equity Standard Listing Requirement
15. November 2013 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 15, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Third-Quarter and Nine-Month 2013 Financial Results
12. November 2013 16:05 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present at the 2013 Therapeutic Area Partnerships Conference
12. November 2013 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...